Verve Capital Limited's Schedule 13G Filing for Vor Biopharma Inc.

Verve Capital Limited filed a Schedule 13G with the SEC, disclosing its beneficial ownership of shares in Vor Biopharma Inc. The filing indicates that Verve Capital Limited holds pre-funded warrants exercisable for up to 2,000,000 shares of common stock, but due to a Beneficial Ownership Blocker, it is currently limited to owning no more than 760,699 shares. This represents 9.9% of the outstanding shares, based on the total shares reported in Vor Biopharma's Form S-3 filed on September 24, 2025. The filing also includes details on the voting and dispositive powers of the shares held by Verve Capital Limited. The certification states that the shares were not acquired for the purpose of influencing the control of the issuer.